Gastroenterology

A recent study has found statins are underutilized for NASH and NAFLD patients.

The issuance comes within a week of the planned PDUFA date for the drug's possible indication as an adult CKD therapy.

The researchers found sero-protection rate at 12-month was significantly higher in the ID arm compared to the IM cohort.

This patient group was at an increased risk for future exposure to systemic corticosteroids and anti-TNF biologics.

Biologic use was not associated with an increased risk of hepatitis B virus flares.

Patients with IBD have an increased risk of developing a C difficile infection in comparison to the general population.

More than 56% of these patients enrolled in TARGET-NASH were being treated with statins.

About 25% of IBD patients with CDI had a history of antibiotic use.

One theory as to why IBD patients are more susceptible to CDI is the use of immunosuppressant treatments.

This edition of HCPLive® State of the Science involves 3 experts discussing different trends in IBD treatments and care.

96.4% of patients in symptomatic remission at week 152 were corticosteroid-free.

Several different treatments appear to be efficacious in this patient population.

A maternal-infant HCV linkage program in combination with a multidisciplinary clinic to collocate mother and infant care was implemented in 2016.

The overall serum anti-toxin A and B antibody levels were similar at baseline between immunocompromised hosts and non-immunocompromised hosts.

Telemedicine could be useful if it is added to regimen of in-person health care visits.

Cases were identified by searching the Veterans Affairs Corporate Data Warehouse.

The treatment resulted in a significant reduction in expression of genes representing T & B lymphocytes, plasma cells/plasmablasts, and myeloid cells.

IDSA and SHEA released 3 new evidence-based recommendations for treating CDI.

Only 5 patients treated with antibiotic prophylaxis developed bacteremia.

Diabetes, obesity, and older age are considered main risk factors that yield non-responses to different HBV vaccines.

Nearly half of all never C difficile cases are found in nursing home communities.

The overall 90-day cumulative incidences of a first CDI episode was 1.9%.

Researchers found no difference between the risk of death or mechanical ventilation based on different IBD Treatments.

Strain typing data is not often available to assess whether recurrence is due to CDI relapse or reinfection.

It could take up to 10 years to develop new treatments for inflammatory bowel disease.